- Home
- RAND vs ANL Comparison
RAND vs ANL Comparison
Compare RAND & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RAND | ANL |
|---|---|---|
| Founded | 1969 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 52.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | RAND | ANL |
|---|---|---|
| Price | $17.00 | $1.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.4K | ★ 28.8K |
| Earning Date | 11-07-2025 | 04-20-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,327,287.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.25 | $0.88 |
| 52 Week High | $31.89 | $2.99 |
Technical Indicators
Market Signals| Indicator | RAND | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 67.10 | 61.06 |
| Support Level | $15.65 | $0.88 |
| Resistance Level | $17.49 | $1.59 |
| Average True Range (ATR) | 0.60 | 0.18 |
| MACD | 0.25 | 0.04 |
| Stochastic Oscillator | 72.17 | 92.82 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.